Literature DB >> 15977647

Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child.

Kathryn McFadden1, Ronald L Hamilton, Sam J Insalaco, Lawrence Lavine, Majeed Al-Mateen, Guoji Wang, Clayton A Wiley.   

Abstract

Neuronal intranuclear inclusion disease (NIID) is a rare and heterogeneous group of slowly progressive neurodegenerative disorders characterized by the widespread presence of eosinophilic neuronal intranuclear inclusions (NII) accompanied by a more restricted pattern of neuronal loss. We report here the pathologic findings in a 13-year-old boy who died after a 6-year clinical history of progressive ataxia, extrapyramidal manifestations, and lower motor neuron abnormalities. Histological evaluation of the brain revealed widespread NII in most neurons. Marked loss of cerebellar Purkinje cells and neurons in the dentate nucleus, red nucleus, and spinal cord anterior horns was accompanied by a modest astrocytosis. Because of the abundance of NII and the absence of a relationship between NII and neuronal loss or microglial activation, we conclude that loss of cerebellar, brainstem, and spinal cord neurons reflects selective neuronal vulnerability. NII were immunoreactive for ubiquitin, glucocorticoid receptor, and SUMO-1, a small, ubiquitin-like protein purportedly involved in protein transport and gene transcription. NII were non-reactive for polyglutamine (1C2), TATA binding protein, promyelocytic leukemia protein, heat shock protein 90, tau, alpha-synuclein, neurofilament, and beta amyloid. The moderate ubiquitin and strong SUMO-1 staining of NII in juvenile cases is the reverse of the pattern noted in adult diseases, suggesting the two age groups are pathogenically distinct. We suggest that juvenile NIID is a spinocerebellar brainstem ataxic disease possibly related to an abnormality in SUMOylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977647      PMCID: PMC1402362          DOI: 10.1093/jnen/64.6.545

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  27 in total

Review 1.  SUMO, ubiquitin's mysterious cousin.

Authors:  S Müller; C Hoege; G Pyrowolakis; S Jentsch
Journal:  Nat Rev Mol Cell Biol       Date:  2001-03       Impact factor: 94.444

Review 2.  Neuronal intranuclear hyaline inclusion disease.

Authors:  Junko Takahashi-Fujigasaki
Journal:  Neuropathology       Date:  2003-12       Impact factor: 1.906

3.  SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death.

Authors:  Tomoya Terashima; Hiromichi Kawai; Masashi Fujitani; Kengo Maeda; Hitoshi Yasuda
Journal:  Neuroreport       Date:  2002-12-03       Impact factor: 1.837

4.  Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease.

Authors:  J Takahashi; J Tanaka; K Arai; N Funata; T Hattori; T Fukuda; H Fujigasaki; T Uchihara
Journal:  J Neuropathol Exp Neurol       Date:  2001-04       Impact factor: 3.685

5.  Neuronal intranuclear hyaline inclusion disease with polyglutamine-immunoreactive inclusions.

Authors:  J Takahashi; T Fukuda; J Tanaka; M Minamitani; H Fujigasaki; T Uchihara
Journal:  Acta Neuropathol       Date:  2000-05       Impact factor: 17.088

6.  Neuronal nuclear alterations in dentatorubral-pallidoluysian atrophy: ultrastructural and morphometric studies of the cerebellar granule cells.

Authors:  H Takahashi; S Egawa; Y S Piao; S Hayashi; M Yamada; T Shimohata; K Oyanagi; S Tsuji
Journal:  Brain Res       Date:  2001-11-16       Impact factor: 3.252

7.  Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias--triple-labeling immunofluorescence study.

Authors:  T Uchihara; H Fujigasaki; S Koyano; A Nakamura; S Yagishita; K Iwabuchi
Journal:  Acta Neuropathol       Date:  2001-08       Impact factor: 17.088

8.  Hereditary neuronal intranuclear inclusion disease with autonomic failure and cerebellar degeneration.

Authors:  Raffaella Zannolli; Sid Gilman; Simone Rossi; Nila Volpi; Andrea Bernini; Paolo Galluzzi; Daniela Galimberti; Lucia Pucci; Alfonso D'Ambrosio; Guido Morgese; Fabio Giannini
Journal:  Arch Neurol       Date:  2002-08

9.  SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease.

Authors:  D L Pountney; Y Huang; R J Burns; E Haan; P D Thompson; P C Blumbergs; W P Gai
Journal:  Exp Neurol       Date:  2003-11       Impact factor: 5.330

10.  PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases.

Authors:  Junko Takahashi; Hiroto Fujigasaki; Kiyoshi Iwabuchi; Amalia C Bruni; Toshiki Uchihara; Khalid H El Hachimi; Giovanni Stevanin; Alexandra Dürr; Anne Sophie Lebre; Yvon Trottier; Hugues de Thé; Junichi Tanaka; Jean Jacques Hauw; Charles Duyckaerts; Alexis Brice
Journal:  Neurobiol Dis       Date:  2003-08       Impact factor: 5.996

View more
  11 in total

Review 1.  The polyG diseases: a new disease entity.

Authors:  Tongling Liufu; Yilei Zheng; Jiaxi Yu; Yun Yuan; Zhaoxia Wang; Jianwen Deng; Daojun Hong
Journal:  Acta Neuropathol Commun       Date:  2022-05-31       Impact factor: 7.578

2.  SUMO1 Modification of Tau in Progressive Supranuclear Palsy.

Authors:  Hironori Takamura; Yoshiaki Nakayama; Hidefumi Ito; Taiichi Katayama; Paul E Fraser; Shinsuke Matsuzaki
Journal:  Mol Neurobiol       Date:  2022-05-14       Impact factor: 5.682

3.  Visceral neuropathy and intestinal pseudo-obstruction in a murine model of a nuclear inclusion disease.

Authors:  Christine M Clarke; Cara Plata; Bonnie Cole; Karen Tsuchiya; Albert R La Spada; Raj P Kapur
Journal:  Gastroenterology       Date:  2007-08-21       Impact factor: 22.682

Review 4.  Targets and consequences of protein SUMOylation in neurons.

Authors:  Kevin A Wilkinson; Yasuko Nakamura; Jeremy M Henley
Journal:  Brain Res Rev       Date:  2010-04-09

5.  Translation of GGC repeat expansions into a toxic polyglycine protein in NIID defines a novel class of human genetic disorders: The polyG diseases.

Authors:  Manon Boivin; Jianwen Deng; Véronique Pfister; Erwan Grandgirard; Mustapha Oulad-Abdelghani; Bastien Morlet; Frank Ruffenach; Luc Negroni; Pascale Koebel; Hugues Jacob; Fabrice Riet; Anke A Dijkstra; Kathryn McFadden; Wiley A Clayton; Daojun Hong; Hiroaki Miyahara; Yasushi Iwasaki; Jun Sone; Zhaoxia Wang; Nicolas Charlet-Berguerand
Journal:  Neuron       Date:  2021-04-21       Impact factor: 17.173

Review 6.  Protein SUMOylation in neuropathological conditions.

Authors:  Dina B Anderson; Kevin A Wilkinson; Jeremy M Henley
Journal:  Drug News Perspect       Date:  2009-06

Review 7.  Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction.

Authors:  Stéphane Martin; Kevin A Wilkinson; Atsushi Nishimune; Jeremy M Henley
Journal:  Nat Rev Neurosci       Date:  2007-12       Impact factor: 34.870

8.  SUMO3 modification accelerates the aggregation of ALS-linked SOD1 mutants.

Authors:  Takako Niikura; Yoshiko Kita; Yoichiro Abe
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

9.  Multiple reversible encephalitic attacks: a rare manifestation of neuronal intranuclear inclusion disease.

Authors:  Mingming Li; Kai Li; Xin Li; Yun Tian; Lu Shen; Guode Wu; Zaiqiang Zhang; Weian Chen
Journal:  BMC Neurol       Date:  2020-04-08       Impact factor: 2.474

10.  Minimotifs dysfunction is pervasive in neurodegenerative disorders.

Authors:  Surbhi Sharma; Richard J Young; Jingchun Chen; Xiangning Chen; Edwin C Oh; Martin R Schiller
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.